Developer docs
API playgroundTry for free, no card

Search company profiles

PureIMS

Full company profile

uuid000bht4

Namestring
PureIMS
Legal namestring
PureIMS B.V.
Websiteurl
pureims.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

PureIMS B.V. is a privately held, clinical-stage pharmaceutical company headquartered in Roden, the Netherlands, founded in 2014 as a University of Groningen spin-off. The company develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, which is built around patented Air Classifier Technology that uses the patient's inhalation breath to disperse dry powder formulations into particles sized for deep lung deposition. PureIMS offers single-use (Cyclops® Classic) and multi-use (Cyclops® Switch and Cyclops® Charge) device variants, with high nominal dose capacity (5-100 mg), 90-100% drug loads, and fine particle fractions of 75-95%.

PureIMS's product pipeline includes Colistin Cyclops® (cystic fibrosis and bronchiectasis, granted EMA and FDA Orphan Drug Designation in December 2024), Levodopa Cyclops® (Parkinson's disease OFF episodes, pursuing 505(b)(2) pathway with demonstrated bioequivalence to Inbrija®), Epinephrine Cyclops® (anaphylaxis), Tobramycin Cyclops® and Amikacin Cyclops® (pulmonary infections and tuberculosis), and inhaled cannabinoid products co-developed with Cannovex (Phase I planned for 2027). Colistin Cyclops® is currently the only commercially available product, distributed as a magistral/extemporaneous preparation in the Netherlands through Fagron and Infinity Pharma, with over 100,000 doses prescribed since 2015.

The company operates a sales-led, hybrid business model combining Dutch magistral product distribution with global licensing and co-development agreements to pharma and biotech partners. Revenue streams include hardware sales of magistral preparations, licensing and royalty agreements, outlicensing of internal pipeline assets, and venture/foundation funding (notably a 2023 round led by Boost-UP Foundation). PureIMS is preparing a Series A financing of approximately €20-25 million to advance lead programs to marketing authorization in the EU and US.

Short descriptiontext

PureIMS is a Dutch clinical-stage pharmaceutical company developing the proprietary Cyclops® dry powder inhaler platform for pulmonary delivery of therapeutics, serving cystic fibrosis, Parkinson's, anaphylaxis, and respiratory infection patients through licensing partners and Dutch magistral distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRoden, Netherlands
HQ citystring
Roden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dry powder inhalers, pulmonary drug delivery, inhalation therapeutics, pharmaceutical compounding, DPI technology platform
Industry4 codes
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Inhalation Pharmaceuticals / Dry Powder Inhaler Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales (Named Patient/Magistral Use)
TypeHardware Sales
Description

Sales of Colistin Cyclops® as an extemporaneously produced (magistral) preparation in the Netherlands for cystic fibrosis and bronchiectasis patients. Product distributed through Fagron/Infinity Pharma partnership.

pureims.com
2Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Revenue from partnering with pharma/biotech companies for development of Cyclops®-based inhalation products. Partners include Cannovex (cannabinoids), and others for antibiotics, vaccines, biologics, and other therapeutics.

pureims.com
3Outlicensing of Pipeline Products
TypeLicensing Royalties
Description

PureIMS maintains internal pipeline products (Levodopa Cyclops®, Epinephrine Cyclops®, Tobramycin Cyclops®, Amikacin Cyclops®) available for in-licensing to pharma partners.

pureims.com
4Investment Funding
TypeAffiliate Referral
Description

Venture capital and foundation funding to support clinical development of Cyclops® technology and pipeline products.

finsmes.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Named patient/magistral use product (Colistin Cyclops®)
ModelOtherBilling cadencePay-as-you-go
Notes

Colistin Cyclops® is an unregistered medicine in development, available under EMA and Dutch Health Inspectorate (IGJ) provisions for magistral use. Not publicly priced.

pureims.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Colistin Cyclops
Description

Pre-filled colistin dry powder inhaler for treatment of pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis.

pureims.com
+7 more records
Core offering1 text field

PureIMS develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, a pre-filled, breath-powered, credit card-sized inhaler using patented Air Classifier Technology for pulmonary drug delivery. The company sells Cyclops®-based products directly (Colistin Cyclops® as a magistral preparation in the Netherlands) and through co-development/licensing partnerships with pharma and biotech firms, building a pipeline across antibiotics (cystic fibrosis, bronchiectasis, tuberculosis), Parkinson's disease rescue therapy, anaphylaxis, and cannabinoid therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Deep lung deposition estimated at 50-60% of nominal dose with fine particle fractions of 75-95%
+6 more records
Product overview1 text field

PureIMS offers the Cyclops® dry powder inhaler platform as its core technology, with multiple product variants (Cyclops®Classic for single-use, Cyclops®Switch and Cyclops®Charge for multi-use) and a portfolio of therapeutic applications. The product portfolio includes Colistin Cyclops® (cystic fibrosis/bronchiectasis, with EMA/FDA Orphan Drug Designation), Levodopa Cyclops® (Parkinson's disease OFF episodes, 505(b)(2) pathway), Epinephrine Cyclops® (anaphylaxis), Tobramycin Cyclops® (pulmonary infections), Amikacin Cyclops® (tuberculosis), and cannabinoid pharmaceuticals developed with partner Cannovex. The Cyclops® platform uses patented Air Classifier Technology for efficient dispersion with minimal excipients.

Product and service10 records
1Cyclops® Dry Powder Inhaler Platform
CategoryDry Powder Inhaler Technology Platform
Description

Proprietary pre-filled, breath-powered dry powder inhaler platform using patented Air Classifier Technology to disperse dry powder formulations into small particles for deep lung deposition. Available in single-use (Cyclops® Classic) and multi-use versions (Cyclops® Switch and Cyclops® Charge). Delivers nominal doses of 5–100 mg with 90–100% drug loads, fine particle fractions of 75–95%, and 50–60% deep lung deposition. Used by PureIMS for its own pipeline and offered to pharma/biotech partners for co-development.

2Colistin Cyclops®
CategoryInhaled Antibiotic
Description

Pre-filled colistin dry powder inhaler for the treatment of pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Offers a patient-friendly alternative to nebulization with easy-to-use, pre-filled, and disposable design. Available as a magistral product in the Netherlands through Fagron/Infinity Pharma. Received EMA and FDA Orphan Drug Designation in late 2024.

3Levodopa Cyclops®
CategoryInhaled Neurological Therapeutic
Description

Levodopa dry powder inhaler for fast and reliable relief of OFF episodes in Parkinson's disease. Provides faster onset of action and more flexible dosing than most other treatments. Demonstrated bioequivalence to Inbrija® in comparative PK studies. Pursuing a 505(b)(2) abbreviated regulatory pathway.

4Epinephrine Cyclops®
CategoryInhaled Emergency Therapeutic
Description

Pre-loaded disposable breath-powered epinephrine dry powder inhaler for the fast and reliable treatment of allergies and impending anaphylaxis. Non-invasive, easy to handle, with fast onset of action. Credit card size for excellent portability. Designed as a more affordable, needle-free alternative to epinephrine auto-injectors.

5Tobramycin Cyclops®
CategoryInhaled Antibiotic
Description

Tobramycin dry powder inhaler for the treatment of pulmonary Pseudomonas aeruginosa infections. Designed for use as part of continuous alternating therapy with inhaled colistin, offering patients the ease and comfort of Cyclops® throughout their treatment cycle.

6Amikacin Cyclops®
CategoryInhaled Antibiotic (Anti-Mycobacterial)
Description

Amikacin dry powder inhaler for the treatment of tuberculosis (TB) or non-tuberculous mycobacterial (NTM) infections. Aims to achieve higher amikacin concentrations in the lungs than conventional infusion or injection, potentially decreasing contagiousness more rapidly.

7Inhaled Cannabinoid Pharmaceuticals (Cyclops®)
CategoryInhaled Cannabinoid Pharmaceutical
Description

Inhaled pharmaceutical cannabinoid products developed through the strategic partnership with Cannovex. Combines Cannovex's proprietary cannabinoid formulations with PureIMS's Cyclops® DPI platform for pharmaceutical-grade development, targeting a range of active ingredients and indications.

8Cyclops® Classic (Single-Use DPI)
CategoryDry Powder Inhaler Device Variant
Description

Single-use dry powder inhaler model from the Cyclops® family, to be discarded after one use. Available in multiple colors and extensively tested with small molecule formulations, biologics, and vaccines with excellent results for dose emission and dispersion.

9Cyclops® Switch (Multi-Use DPI)
CategoryDry Powder Inhaler Device Variant
Description

Multi-use dry powder inhaler model with a non-removable slidable cartridge containing two separate pre-filled dose compartments. Can hold either one dose comprising two inhalations or two separate doses at different time points. Patent protected until 2043.

10Cyclops® Charge (Multi-Use DPI)
CategoryDry Powder Inhaler Device Variant
Description

Multi-use dry powder inhaler model allowing pre-filled cartridges with a single dose compartment to be easily replaced after emptying by inhalation. Suitable for weekly dosing regimens without the need for cleaning. Patent protected until 2043.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Cannovex
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Strategic co-development partnership to develop pharmaceutical cannabinoid products using PureIMS's Cyclops® DPI. Cannovex holds exclusive rights for range of active ingredients and indications. Phase I clinical trials slated to begin in 2027. Validates versatility of Cyclops® platform.

pureims.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

Fagron granted exclusive rights to organize national distribution of PureIMS's compounded preparations in the Netherlands including inhaled antibiotic for pulmonary Pseudomonas aeruginosa infections caused by cystic fibrosis. Fagron distributes through Infinity Pharma.

3Infinity Pharma
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

Specializes in patient-specific drug compounding and equipped to provide active patient support. Manages dispensing of Cyclops® products nationwide in the Netherlands ensuring short delivery timeframes.

pureims.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing academic collaboration with Department of Pharmaceutical Technology and Biopharmacy. Multiple scientific publications co-authored. Source of Cyclops® DPI technology origin.

5University Medical Center Groningen (UMCG)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Department of Lung Diseases and Tuberculosis, Department of Allergology, and Pediatric Pulmonology. Conducted clinical trials for Colistin Cyclops® and Amikacin Cyclops®.

pureims.com
6Harro Höfliger Verpackungsmaschinen GmbH
Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

Manufacturing equipment partner for scalable Cyclops® production. Published article on PureIMS in Harro Magazine. Strong partnerships with leading market-scale production line developers.

pureims.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-development partner pursuing pulmonary delivery of antibiotics using Cyclops® platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration partner listed on PureIMS website for various development projects.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish clinical-stage company developing proprietary dry powder inhalers (ICOcap, ICOone, ICOres) for generic and novel inhaled therapeutics. Iconovo is the closest functional peer to PureIMS—same business model of providing a DPI platform for co-development and licensing with pharma partners, at a comparable early-stage scale.

TypeDirect peer
Description

US-listed company commercializing the Technosphere® breath-powered dry powder inhalation platform (Afrezza, V-Go, Tyvaso DPI after United Therapeutics licensing). MannKind is a direct platform peer—breath-powered DPI delivering high drug load to deep lung—and serves as a useful comparable for the licensing/royalty business model PureIMS is pursuing.

TypeBroad incumbent
Description

Vectura is a long-established DPI/inhalation technology developer acquired by Philip Morris, offering formulation and device platforms (e.g., GyroHaler, LeverHaler, Fox) to pharma partners. It is a broader incumbent peer that validates the platform-licensing business model but operates at far greater scale and across more therapeutic areas.

4Civitas Therapeutics / Acorda Therapeutics
TypeDirect peer
Description

Civitas developed the ARCUS® DPI platform used to deliver Inbrija® (inhaled levodopa) for Parkinson's disease OFF episodes—the very drug that PureIMS's Levodopa Cyclops® has demonstrated bioequivalence to. This makes Civitas/Acorda the single most direct competitive comparator for PureIMS's lead CNS program.

5Aradigm Corporation (Grifols)
TypeDirect peer
Description

Aradigm developed the AERx® inhalation platform and led inhaled liposomal antibiotic programs (e.g., Linaprazid) targeting pulmonary infections including cystic fibrosis. It is a direct peer in the inhaled antibiotics space and was acquired by Grifols, illustrating one potential exit pathway for PureIMS.

TypeEmerging player
Description

US clinical-stage company developing inhaled therapeutics using the iSPERSE® dry powder technology for respiratory diseases including cystic fibrosis and COPD. Pulmatrix is an emerging peer with overlapping indications (pulmonary infections) and a similar co-development/licensing go-to-market approach.

TypeOthers
Description

Portuguese CDMO with deep inhalation drug development and DPI manufacturing capabilities, partnering with pharma companies on inhaled formulations. Hovione is an adjacent enabling partner—PureIMS uses Harro Höfliger for production scaling, and Hovione represents a similar enabling-services peer in the inhalation CDMO ecosystem.

TypeEmerging player
Description

US clinical-stage company developing inhaled therapies (e.g., AP01 for IPF) for pulmonary diseases. Avalyn is an emerging peer with overlapping inhaled-therapeutic positioning and similar phase-stage development, comparable as a fundraising and licensing comparable for PureIMS.

TypeEmerging player
Description

Clinical-stage biotech developing iSPERSE-based inhaled therapeutics for respiratory infections including COVID-19, influenza and cystic fibrosis. Inhalon is an emerging peer with overlapping pulmonary anti-infective focus and similar licensing-oriented business model.

TypeEmerging player
Description

Early-stage company developing inhaled therapies for pulmonary and respiratory diseases, with focus on reformulating existing drugs for DPI delivery. Respira is an emerging peer in the same niche of using inhalation to improve established molecules.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PureIMS

Inhalation Pharmaceuticals / Dry Powder Inhaler Technologypureims.com

PureIMS is a Dutch clinical-stage pharmaceutical company developing the proprietary Cyclops® dry powder inhaler platform for pulmonary delivery of therapeutics, serving cystic fibrosis, Parkinson's, anaphylaxis, and respiratory infection patients through licensing partners and Dutch magistral distribution.

What PureIMS does

PureIMS B.V. is a privately held, clinical-stage pharmaceutical company headquartered in Roden, the Netherlands, founded in 2014 as a University of Groningen spin-off. The company develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, which is built around patented Air Classifier Technology that uses the patient's inhalation breath to disperse dry powder formulations into particles sized for deep lung deposition. PureIMS offers single-use (Cyclops® Classic) and multi-use (Cyclops® Switch and Cyclops® Charge) device variants, with high nominal dose capacity (5-100 mg), 90-100% drug loads, and fine particle fractions of 75-95%.

PureIMS's product pipeline includes Colistin Cyclops® (cystic fibrosis and bronchiectasis, granted EMA and FDA Orphan Drug Designation in December 2024), Levodopa Cyclops® (Parkinson's disease OFF episodes, pursuing 505(b)(2) pathway with demonstrated bioequivalence to Inbrija®), Epinephrine Cyclops® (anaphylaxis), Tobramycin Cyclops® and Amikacin Cyclops® (pulmonary infections and tuberculosis), and inhaled cannabinoid products co-developed with Cannovex (Phase I planned for 2027). Colistin Cyclops® is currently the only commercially available product, distributed as a magistral/extemporaneous preparation in the Netherlands through Fagron and Infinity Pharma, with over 100,000 doses prescribed since 2015.

The company operates a sales-led, hybrid business model combining Dutch magistral product distribution with global licensing and co-development agreements to pharma and biotech partners. Revenue streams include hardware sales of magistral preparations, licensing and royalty agreements, outlicensing of internal pipeline assets, and venture/foundation funding (notably a 2023 round led by Boost-UP Foundation). PureIMS is preparing a Series A financing of approximately €20-25 million to advance lead programs to marketing authorization in the EU and US.

PureIMS firmographics

Firmographics
Name
PureIMS
Legal name
PureIMS B.V.
Website
https://pureims.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
PureIMS is a Dutch clinical-stage pharmaceutical company developing the proprietary Cyclops® dry powder inhaler platform for pulmonary delivery of therapeutics, serving cystic fibrosis, Parkinson's, anaphylaxis, and respiratory infection patients through licensing partners and Dutch magistral distribution.
Ownership category
akta.pro rank

PureIMS industry classification

Industry
Product category
Inhalation Pharmaceuticals / Dry Powder Inhaler Technology
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

Keywords

  • Dry powder inhalers
  • Pulmonary drug delivery
  • Inhalation therapeutics
  • Pharmaceutical compounding
  • DPI technology platform

Where PureIMS is headquartered

Location

Headquarters

HQ city
Roden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

PureIMS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Product Sales (Named Patient/Magistral Use): Sales of Colistin Cyclops® as an extemporaneously produced (magistral) preparation in the Netherlands for cystic fibrosis and bronchiectasis patients. Product distributed through Fagron/Infinity Pharma partnership.
  2. Licensing and Co-development Agreements: Revenue from partnering with pharma/biotech companies for development of Cyclops®-based inhalation products. Partners include Cannovex (cannabinoids), and others for antibiotics, vaccines, biologics, and other therapeutics.
  3. Outlicensing of Pipeline Products: PureIMS maintains internal pipeline products (Levodopa Cyclops®, Epinephrine Cyclops®, Tobramycin Cyclops®, Amikacin Cyclops®) available for in-licensing to pharma partners.
  4. Investment Funding: Venture capital and foundation funding to support clinical development of Cyclops® technology and pipeline products.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNamed patient/magistral use product (Colistin Cyclops®)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

PureIMS product offering

Product offering

Core offering

PureIMS develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, a pre-filled, breath-powered, credit card-sized inhaler using patented Air Classifier Technology for pulmonary drug delivery. The company sells Cyclops®-based products directly (Colistin Cyclops® as a magistral preparation in the Netherlands) and through co-development/licensing partnerships with pharma and biotech firms, building a pipeline across antibiotics (cystic fibrosis, bronchiectasis, tuberculosis), Parkinson's disease rescue therapy, anaphylaxis, and cannabinoid therapeutics.

Product overview

PureIMS offers the Cyclops® dry powder inhaler platform as its core technology, with multiple product variants (Cyclops®Classic for single-use, Cyclops®Switch and Cyclops®Charge for multi-use) and a portfolio of therapeutic applications. The product portfolio includes Colistin Cyclops® (cystic fibrosis/bronchiectasis, with EMA/FDA Orphan Drug Designation), Levodopa Cyclops® (Parkinson's disease OFF episodes, 505(b)(2) pathway), Epinephrine Cyclops® (anaphylaxis), Tobramycin Cyclops® (pulmonary infections), Amikacin Cyclops® (tuberculosis), and cannabinoid pharmaceuticals developed with partner Cannovex. The Cyclops® platform uses patented Air Classifier Technology for efficient dispersion with minimal excipients.

Differentiator

Problem solved

Functional benefit

Brands

  • Colistin Cyclops: Pre-filled colistin dry powder inhaler for treatment of pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis.
  • Levodopa Cyclops
  • Epinephrine Cyclops
  • Tobramycin Cyclops
  • Amikacin Cyclops
  • Cyclops Classic
  • Cyclops Switch
  • Cyclops Charge

Products and services

  • Cyclops® Dry Powder Inhaler Platform Proprietary pre-filled, breath-powered dry powder inhaler platform using patented Air Classifier Technology to disperse dry powder formulations into small particles for deep lung deposition. Available in single-use (Cyclops® Classic) and multi-use versions (Cyclops® Switch and Cyclops® Charge). Delivers nominal doses of 5–100 mg with 90–100% drug loads, fine particle fractions of 75–95%, and 50–60% deep lung deposition. Used by PureIMS for its own pipeline and offered to pharma/biotech partners for co-development.
  • Colistin Cyclops® Pre-filled colistin dry powder inhaler for the treatment of pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Offers a patient-friendly alternative to nebulization with easy-to-use, pre-filled, and disposable design. Available as a magistral product in the Netherlands through Fagron/Infinity Pharma. Received EMA and FDA Orphan Drug Designation in late 2024.
  • Levodopa Cyclops® Levodopa dry powder inhaler for fast and reliable relief of OFF episodes in Parkinson's disease. Provides faster onset of action and more flexible dosing than most other treatments. Demonstrated bioequivalence to Inbrija® in comparative PK studies. Pursuing a 505(b)(2) abbreviated regulatory pathway.
  • Epinephrine Cyclops® Pre-loaded disposable breath-powered epinephrine dry powder inhaler for the fast and reliable treatment of allergies and impending anaphylaxis. Non-invasive, easy to handle, with fast onset of action. Credit card size for excellent portability. Designed as a more affordable, needle-free alternative to epinephrine auto-injectors.
  • Tobramycin Cyclops® Tobramycin dry powder inhaler for the treatment of pulmonary Pseudomonas aeruginosa infections. Designed for use as part of continuous alternating therapy with inhaled colistin, offering patients the ease and comfort of Cyclops® throughout their treatment cycle.
  • Amikacin Cyclops® Amikacin dry powder inhaler for the treatment of tuberculosis (TB) or non-tuberculous mycobacterial (NTM) infections. Aims to achieve higher amikacin concentrations in the lungs than conventional infusion or injection, potentially decreasing contagiousness more rapidly.
  • Inhaled Cannabinoid Pharmaceuticals (Cyclops®) Inhaled pharmaceutical cannabinoid products developed through the strategic partnership with Cannovex. Combines Cannovex's proprietary cannabinoid formulations with PureIMS's Cyclops® DPI platform for pharmaceutical-grade development, targeting a range of active ingredients and indications.
  • Cyclops® Classic (Single-Use DPI) Single-use dry powder inhaler model from the Cyclops® family, to be discarded after one use. Available in multiple colors and extensively tested with small molecule formulations, biologics, and vaccines with excellent results for dose emission and dispersion.
  • Cyclops® Switch (Multi-Use DPI) Multi-use dry powder inhaler model with a non-removable slidable cartridge containing two separate pre-filled dose compartments. Can hold either one dose comprising two inhalations or two separate doses at different time points. Patent protected until 2043.
  • Cyclops® Charge (Multi-Use DPI) Multi-use dry powder inhaler model allowing pre-filled cartridges with a single dose compartment to be easily replaced after emptying by inhalation. Suitable for weekly dosing regimens without the need for cleaning. Patent protected until 2043.

Quantifiable outcome

  • Deep lung deposition estimated at 50-60% of nominal dose with fine particle fractions of 75-95%
  • +6 more outcomes

Companies that use PureIMS

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

PureIMS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PureIMS partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, secondary and minor.

  • CannovexcoreStrategic or Co-development Partner · 1 March 2026Strategic co-development partnership to develop pharmaceutical cannabinoid products using PureIMS's Cyclops® DPI. Cannovex holds exclusive rights for range of active ingredients and indications. Phase I clinical trials slated to begin in 2027. Validates versatility of Cyclops® platform.
  • FagroncoreChannel Partner/ Reseller/ Distributor · 1 September 2024Fagron granted exclusive rights to organize national distribution of PureIMS's compounded preparations in the Netherlands including inhaled antibiotic for pulmonary Pseudomonas aeruginosa infections caused by cystic fibrosis. Fagron distributes through Infinity Pharma.
  • Infinity PharmasecondaryChannel Partner/ Reseller/ Distributor · 1 September 2024Specializes in patient-specific drug compounding and equipped to provide active patient support. Manages dispensing of Cyclops® products nationwide in the Netherlands ensuring short delivery timeframes.
  • University of GroningencoreStrategic or Co-development PartnerLong-standing academic collaboration with Department of Pharmaceutical Technology and Biopharmacy. Multiple scientific publications co-authored. Source of Cyclops® DPI technology origin.
  • University Medical Center Groningen (UMCG)coreStrategic or Co-development PartnerCollaboration with Department of Lung Diseases and Tuberculosis, Department of Allergology, and Pediatric Pulmonology. Conducted clinical trials for Colistin Cyclops® and Amikacin Cyclops®.
  • Harro Höfliger Verpackungsmaschinen GmbHsecondaryImplementation/ SI/ Consulting PartnerManufacturing equipment partner for scalable Cyclops® production. Published article on PureIMS in Harro Magazine. Strong partnerships with leading market-scale production line developers.
  • Adjutec PharmaminorStrategic or Co-development PartnerCo-development partner pursuing pulmonary delivery of antibiotics using Cyclops® platform.
  • Interventional Medical Device SolutionsminorStrategic or Co-development PartnerCollaboration partner listed on PureIMS website for various development projects.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

PureIMS competitors and assessment

Company assessment

Direct peers

  • Iconovo: Swedish clinical-stage company developing proprietary dry powder inhalers (ICOcap, ICOone, ICOres) for generic and novel inhaled therapeutics. Iconovo is the closest functional peer to PureIMS—same business model of providing a DPI platform for co-development and licensing with pharma partners, at a comparable early-stage scale.
  • MannKind Corporation: US-listed company commercializing the Technosphere® breath-powered dry powder inhalation platform (Afrezza, V-Go, Tyvaso DPI after United Therapeutics licensing). MannKind is a direct platform peer—breath-powered DPI delivering high drug load to deep lung—and serves as a useful comparable for the licensing/royalty business model PureIMS is pursuing.
  • Civitas Therapeutics / Acorda Therapeutics: Civitas developed the ARCUS® DPI platform used to deliver Inbrija® (inhaled levodopa) for Parkinson's disease OFF episodes—the very drug that PureIMS's Levodopa Cyclops® has demonstrated bioequivalence to. This makes Civitas/Acorda the single most direct competitive comparator for PureIMS's lead CNS program.
  • Aradigm Corporation (Grifols): Aradigm developed the AERx® inhalation platform and led inhaled liposomal antibiotic programs (e.g., Linaprazid) targeting pulmonary infections including cystic fibrosis. It is a direct peer in the inhaled antibiotics space and was acquired by Grifols, illustrating one potential exit pathway for PureIMS.

Broad incumbents

  • Vectura Group (Philip Morris International): Vectura is a long-established DPI/inhalation technology developer acquired by Philip Morris, offering formulation and device platforms (e.g., GyroHaler, LeverHaler, Fox) to pharma partners. It is a broader incumbent peer that validates the platform-licensing business model but operates at far greater scale and across more therapeutic areas.

Emerging players

  • Pulmatrix: US clinical-stage company developing inhaled therapeutics using the iSPERSE® dry powder technology for respiratory diseases including cystic fibrosis and COPD. Pulmatrix is an emerging peer with overlapping indications (pulmonary infections) and a similar co-development/licensing go-to-market approach.
  • Avalyn Pharma: US clinical-stage company developing inhaled therapies (e.g., AP01 for IPF) for pulmonary diseases. Avalyn is an emerging peer with overlapping inhaled-therapeutic positioning and similar phase-stage development, comparable as a fundraising and licensing comparable for PureIMS.
  • Inhalon Biopharma: Clinical-stage biotech developing iSPERSE-based inhaled therapeutics for respiratory infections including COVID-19, influenza and cystic fibrosis. Inhalon is an emerging peer with overlapping pulmonary anti-infective focus and similar licensing-oriented business model.
  • Respira Therapeutics: Early-stage company developing inhaled therapies for pulmonary and respiratory diseases, with focus on reformulating existing drugs for DPI delivery. Respira is an emerging peer in the same niche of using inhalation to improve established molecules.

Others

  • Hovione: Portuguese CDMO with deep inhalation drug development and DPI manufacturing capabilities, partnering with pharma companies on inhaled formulations. Hovione is an adjacent enabling partner—PureIMS uses Harro Höfliger for production scaling, and Hovione represents a similar enabling-services peer in the inhalation CDMO ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

PureIMS social profiles

Digital presence

PureIMS compliance and trust

Trust signal

Compliance2 records

PureIMS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PureIMS leadership team

Management profile

Number of profiles

Profiles10 records

PureIMS subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PureIMS funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PureIMS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PureIMS

What does PureIMS do?

PureIMS develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, a pre-filled, breath-powered, credit card-sized inhaler using patented Air Classifier Technology for pulmonary drug delivery. The company sells Cyclops®-based products directly (Colistin Cyclops® as a magistral preparation in the Netherlands) and through co-development/licensing partnerships with pharma and biotech firms, building a pipeline across antibiotics (cystic fibrosis, bronchiectasis, tuberculosis), Parkinson's disease rescue therapy, anaphylaxis, and cannabinoid therapeutics.

Is PureIMS a public or private company?

PureIMS is a private company. It is classified as venture growth investor backed and is currently operating.

When was PureIMS founded?

PureIMS was founded in 2014. It employs 1 to 10 people.

Where is PureIMS based?

PureIMS is headquartered in Roden, Netherlands, in the Europe region.

How does PureIMS make money?

Four revenue lines are on record. Product Sales (Named Patient/Magistral Use) is the primary driver. The others are licensing and Co-development Agreements, outlicensing of Pipeline Products and investment Funding.

Who are PureIMS's main competitors?

Direct peers on record are Iconovo, MannKind Corporation, Civitas Therapeutics / Acorda Therapeutics and Aradigm Corporation (Grifols). Vectura Group (Philip Morris International) is listed as a broad incumbent. Emerging players are Pulmatrix, Avalyn Pharma, Inhalon Biopharma and Respira Therapeutics. Hovione is listed as an others.

Does PureIMS have an API?

No public API is recorded for PureIMS.

What industry is PureIMS in?

PureIMS's product category is Inhalation Pharmaceuticals / Dry Powder Inhaler Technology. Its primary akta.pro industry code is HLAHAIAI, Inhalers (MDI/DPI/SMI), with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals